comparemela.com

Latest Breaking News On - Daniel pearlstein - Page 5 : comparemela.com

POINT Biopharma Prices Public Offering of Common Stock

INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the.

New yorkUnited statesDaniel pearlsteinPiper sandlerEquity syndicate departmentGuggenheim securitiesOppenheimer coBiopharma global incExchange commissionSyndicate prospectus departmentProspectus departmentPiper sandler coCommon stockPrivate securities litigation reform actRelations contactNasdaq pnt

POINT Biopharma Provides Updated Efficacy and Safety Data

Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A.

United kingdomUnited statesKim chiDaniel pearlsteinNeil fleshnerAaronr hansenScott tagawaOliver sartorUniversity of torontoProfessor of medicine at meyer cancer centerUniversity of queenslandBiopharma global incChief medical officerDeputy directorCancer servicesMetro south health

POINT Biopharma Announces Poster Presentation at ESMO

Poster #1400P will be presented on Sunday, September 11 by Dr. Aaron R. .

United statesFrance generalUnited kingdomDaniel pearlsteinAaronr hansenUniversity of torontoBiopharma global incSpecific membrane antigenMetastatic castration resistant prostate cancerInitial resultsPrincess alexandra hospitalAssociate professorNorth americaPrivate securities litigation reform actRelations contactNasdaq pnt

POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesFrance generalUnited kingdomSherin al safadiKim chiDaniel pearlsteinOliver sartorUniversity of tulane school medicineBritish columbia cancer agencyTulane cancer centerVp medical affairsBiopharma global incSpecific membrane antigenMetastatic castration resistant prostate cancerInitial resultsMedical director

POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United statesUnited kingdomJoe mccannDaniel pearlsteinNovartis institutes for biomedical researchRutgers business schoolUniversity of guelphSociety for nuclear medicineBiopharma global incDevelopment expensesAmerican association for cancer researchWilfrid laurier universityEuropean unionHealth canadaNorth americaAmerican association

vimarsana © 2020. All Rights Reserved.